Table 1 Baseline clinical and demographic characteristics of 245 patients
Characteristics | Results |
|---|---|
Mean age at induction, years (range) | 39.9 (15–87) |
Gender, n (%) | |
Female | 136 (55.5) |
Male | 109 (44.5) |
Mean age at diagnosis, years (range) | 29.1 (6–78) |
Concomitant use of corticosteroids at the beginning of UST treatmenta, n (%) | 135 (60.5) |
Montreal classification, n (%) | |
Age at diagnosis | |
A1 (< 17 years) | 44 (18.0) |
A2 (17–40 years) | 163 (66.5) |
A3 (> 40 years) | 38 (15.5) |
Disease location | |
L1 (ileal) | 55 (22.4) |
L2 (colonic) | 35 (14.3) |
L3 (ileocolonic) | 120 (49.0) |
L4 (upper gastrointestinal tract) | 35 (14.3) |
Behaviour | |
B1 (inflammatory) | 75 (30.6) |
B2/B3 (stenosing/penetrating) | 170 (69.4) |
Mean disease duration, years (range) | 11.0 (0–38) |
Disease duration, years, n (%) | |
0–2 years | 23 (9.4) |
3–10 years | 111 (45.3) |
> 10 years | 111 (45.3) |
Concomitant use of immunosuppressorsb, n (%) | 54 (22.1) |
Previous bowel resection, n (%) | 136 (55.5) |
Perianal diseasec, n (%) | 101 (41.2) |
Active smoking, n (%) | 36 (14.7) |
Anaemia, n (%) | 116 (47.3) |
Previous use of biologics, n (%) | 212 (86.5) |
Number of biologics, n (%) | |
0 | 33 (13.5) |
1 | 71 (29.0) |
2 | 111 (45.3) |
3 | 29 (11.8) |
4 | 1 (0.4) |
Previous exposure of biologics, n (%) | |
Anti-TNF | 182 (74.3) |
Infliximab | 132 (53.9) |
Adalimumab | 127 (51.8) |
Certolizumab pegol | 16 (6.5) |
Anti-integrin | 27 (11.0) |
Vedolizumab | 26 (10.6) |
Etrolizumab | 1 (0.4) |